Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation

Medicine (United States)

Volumn 95, Issue 20, 2016, Pages

  Hsieh, Yu Cheng ^a,b   Hung, Chen Ying ^a,c   Li, Cheng Hung ^a   Liao, Ying Chieh ^a   Huang, Jin Long ^a   Lin, Ching Heng ^a,d   Wu, Tsu Juey ^a,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b PROVIDENCE UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW-ONSET ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; VASCULAR DISEASE; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; PROTECTION; STATISTICS AND NUMERICAL DATA; STROKE; TAIWAN;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; STROKE; TAIWAN;

EID: 84973569778     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003721     Document Type: Article

References (29)

1. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
2. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
3. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-518.
4. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308-328.
5. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace. 2011;13:634-639.
6. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29.
7. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096.
8. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838-854.
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the management of arterial hypertension. Blood Press. 2014;23:3-16.
10. Hung CY, Hsieh YC, Li CH, et al. Age and CHADS2 score predict the effectiveness of renin-Angiotensin system blockers on primary prevention of atrial fibrillation. Sci Rep. 2015;5:11442.
11. Marott SC, Nielsen SF, Benn M, et al. Antihypertensive treatment and risk of atrial fibrillation: A nationwide study. Eur Heart J. 2014;35:1205-1214.
12. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
13. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197-2204.
14. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174-1183.
15. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J. 2007;154:448-453.
16. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens. 2008;26:403-411.
17. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719.
18. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-Analysis. J Am Coll Cardiol. 2005;45:1832-1839.
19. Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-Angiotensin system inhibition a meta-Analysis. J Am Coll Cardiol. 2010;55:2299-2307.
20. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med. 2010;152:78-84.
21. Ma C, Cao J, Lu XC, et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. J Geriatr Cardiol. 2012;9:252-257.
22. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
23. Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich). 2006;8:261-268.
24. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
25. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854-2858.
26. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation. 1998;98:1721-1727.
27. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002;106:331-336.
28. Wong AA, Read SJ. Early changes in physiological variables after stroke. Ann Indian Acad Neurol. 2008;11:207-220.
29. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.